aureus VAP
Clinical biomarker
clinical study
Staphylococcus aureus
diagnostic measures
clinical utility
clinical validation
clinical guidelines
early clinical intervention
unique rapid diagnostic test
diagnostic kit
early treatment
antibiotic treatment
risk of developing VAP
causative pathogen
early identification of patients
leading causes of VAP
novel biomarker
healthcare professionals
ventilator-associated pneumonia Hospital
spread of antibiotic resistance
design
ICU clinician rapid information
spiraling healthcare costs
major human pathogen
Antibiotic stewardship efforts
nosocomial infections
infecting bacteria
prophylactic measures
resistance pattern
feasibility study
overall aim
high mortality rates
complete FTO analysis
use of appropriate antimicrobial therapies
KOLs
end users
dialogue
reimbursement issues
market
characterization
intensive care unit
road-map
effective management
range of EU hospitals
pricing
Arsanis Biosciences
project
potential prevention
concept
approval
bedside
markers
approaches
hours